These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9168075)

  • 1. Changes in serum estrogen levels in women during tamoxifen therapy.
    Lum SS; Woltering EA; Fletcher WS; Pommier RF
    Am J Surg; 1997 May; 173(5):399-402. PubMed ID: 9168075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients.
    Wilking N; Carlström K; Sköldefors H; Theve NO; Wallgren A
    Acta Chir Scand; 1982; 148(4):345-9. PubMed ID: 6215811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
    Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
    J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tamoxifen treatment on estrogen metabolism in postmenopausal women with advanced breast cancer.
    Levin J; Markham MJ; Greenwald ES; O'Connor JF; Zumoff B; Fukushima DK
    Anticancer Res; 1982; 2(6):377-80. PubMed ID: 7168557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serum estrone sulfate levels in patients with breast cancer].
    Yasumura T; Oka T; Honjyo H; Okada H
    Nihon Geka Gakkai Zasshi; 1988 Aug; 89(8):1267-72. PubMed ID: 3185494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
    Ravdin PM; Fritz NF; Tormey DC; Jordan VC
    Cancer Res; 1988 Feb; 48(4):1026-9. PubMed ID: 3123050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
    Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
    Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
    Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
    J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer.
    De Marinis L; Mancini A; Izzi D; Bianchi A; Giampietro A; Fusco A; Liberale I; Rossi S; Valle D
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):681-5. PubMed ID: 10848871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function.
    Manni A; Pearson OH
    Cancer Treat Rep; 1980; 64(6-7):779-85. PubMed ID: 6775808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
    Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
    Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E
    J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
    Rose DP; Davis TE
    Cancer Res; 1980 Nov; 40(11):4043-7. PubMed ID: 6451282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.